Cencora delivered 3.8% and 7.5% revenue and adjusted EPS growth, respectively, during the fiscal second quarter. Both figures landed behind FactSet consensus. Revenue guidance was lowered to 5% growth at the midpoint from the previous 8%. Shares are down 14% at time of writing May 6.
Cencora distributes pharmaceutical products to nearly one-third of the industry, leading to substantial negotiation leverage with drug manufacturers.
Reimbursement pressures on pharmacy and provider customers have led to an emphasis on cost containment, pressuring Cencora's profitability.
|
Metric
|
COR
|
MCK
|
MDLN
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.89 | 20.11 | 65.25 |
Price/Book Value | 16.12 | — | 2.79 |
Price/Sales | 0.17 | 0.24 | 2.01 |
Price/Cash Flow | 14.60 | 15.73 | 24.16 |
|
Metric
|
COR
|
MCK
|
MDLN
|
|---|---|---|---|
Quick Ratio | 0.48 | 0.48 | 2.33 |
Current Ratio | 0.95 | 0.85 | 4.41 |
Interest Coverage | 8.18 | 25.38 | 2.53 |
|
Metric
|
COR
|
MCK
|
MDLN
|
|---|---|---|---|
Return on Assets (Normalized) | 5.17% | 5.96% | 3.10% |
Return on Equity (Normalized) | 201.23% | — | 21.26% |
Return on Invested Capital (Normalized) | 38.43% | 60.93% | 5.57% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| McKesson Corp
MCK
| Qylngnnj | Yjzjpbx | $94B | |||
| Cardinal Health Inc
CAH
| Lhymvqxlt | Cbwdmj | $52B | |||
| Henry Schein Inc
HSIC
| Vvndhsjzc | Nwfrmf | $9B | |||
| Sinopharm Group Co Ltd ADR
SHTDY
| — | Zzfg | $7B | |||
| Sinopharm Group Co Ltd
SHTDF
| — | Vql | $7B | |||
| Galenica Ltd
GALNF
| — | Gwpmwd | $5B | |||
| Medipal Holdings Corp ADR
MAHLY
| — | Ljyv | $3B | |||
| Medipal Holdings Corp
MEPDF
| — | Rrxb | $3B | |||
| Amplifon SpA Az nom Post Frazionamento
AMFPF
| — | Sjvgc | $3B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/b76d1412-e5af-4b94-8222-8cb66fe23dbe.jpg)
United States